L'Agence nationale de la recherche Des projets pour la science

Investissements d'avenirProjets financés


Alliance Parisienne des Instituts de Recherche en Cancérologie (PACRI)


Action : Pôle hospitalier Universitaire Cancer (PHUC)


N° de convention : 11-PHUC-0002

Informations générales

  • Référence projet : 11-PHUC-0002
  • RST : Guido KROEMER
  • Etablissement Coordinateur : COMUE Sorbonne Paris Cité
  • Région du projet : Île-de-France
  • Discipline : 5 - Bio Med
  • Aide allouée : 10 000 000 €
  • Date de début du projet : 01/01/2013
  • Date de fin du projet : 31/12/2017
  • Site web du projet : http://pacri.jimdo.com/
  • Mots clés : Cancer; chemotherapy; immunotherapy; radiotherapy

Résumé du projet

The Paris Alliance of Cancer Research Institutes (PACRI) has been created to spearhead basic, translational and clinical cancer research in the Greater Paris area, which concentrates more than half of the National research output in oncology. PACRI, which is composed by Institut Curie, Gustave Roussy (GR), Institut Universitaire en Hématologie/St. Louis, and University Paris Descartes, has been starting its activities in mid-2013. PACRI has established and consolidated research platforms dedicated to (epi)genetics, bioinformatics, screening and cell biology, as well as to tumor immunology. PACRI has built a network of cell biology facilties allowing for phenotyping screening of anticancer drug effects on cells expressing fluorescent biosensors. In addition, PACRI has created a networked “mouse cancer clinics” designed to monitor drug effects on both xenotransplanted primary human cancers and genetically defined, oncogene-driven murine cancers. PACRI has begun the exploration of selected breakthrough concepts designed to treat cancer, with an emphasis on the integration of genomic and epigenomic data and cell biology studies for drug screening. PACRI is also confirming the hypothesis that, to be successful, cytotoxic and targeted cancer therapies require an anticancer immune response, which in turn is determined by the gut microbiota. In synthesis, PACRI is improving the efficiency of existing – ever more integrated – cancer research facilities, hence making the Greater Paris area (Ile-de-France) a prominent and highly visible center in translational and clinical oncology.    

(L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.)